Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Chimera Antigen Receptor (CAR)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT04240808
What this trial is testing

Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL)

Who this might be right for
Non Hodgkin Lymphoma
University of Colorado, Denver 10
Early research (Phase 1)Looking for participantsNCT06891742
What this trial is testing

Phase I Study of OriC902 in Treatment of Advanced HCC

Who this might be right for
HCC
Peking University 44
Early research (Phase 1)Ended earlyNCT04844086
What this trial is testing

RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies

Who this might be right for
B-cell Acute Lymphoblastic LeukemiaNon-Hodgkin's Lymphoma, RelapsedNon-Hodgkin's Lymphoma Refractory+5 more
Eden BioCell Ltd. 2
Testing effectiveness (Phase 2)Study completedNCT04539444
What this trial is testing

CD19/22 CART Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Lymphoma

Who this might be right for
Relapsed Non Hodgkin LymphomaRefractory Non-Hodgkin Lymphoma
The First Affiliated Hospital of Soochow University 18
Early research (Phase 1)Temporarily pausedNCT06355908
What this trial is testing

IL13Rα2 CAR-T for Patients With r/r Glioma

Who this might be right for
Glioma
Yang Zhang 30
Early research (Phase 1)UnknownNCT03110640
What this trial is testing

Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma

Who this might be right for
B-cell Adult Acute Lymphoblastic LeukemiaB-cell Chronic Lymphocytic LeukemiaAdult Acute Lymphoblastic Leukemia in Remission+2 more
First Affiliated Hospital of Wenzhou Medical University 20
Very early researchLooking for participantsNCT07241468
What this trial is testing

An Exploratory Clinical Study on the Safety and Efficacy of Anti-CD19/BCMA U CAR-T Cells in the Treatment of Relapsed/Refractory Immune-mediated Kidney Disease

Who this might be right for
Relapsed/Refractory Immune NephropathyRelapsed/Refractory Immune-mediated Kidney Disease
Changhai Hospital 36
Early research (Phase 1)Looking for participantsNCT07403097
What this trial is testing

Study of CD19 CAR-T Therapy for Refractory SLE

Who this might be right for
Systemic Lupus Erythematosus
Chongqing Precision Biotech Co., Ltd 18
Early research (Phase 1)Study completedNCT04231747
What this trial is testing

CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Who this might be right for
Lymphoma Non-HodgkinAgressive LymphomaDiffuse-large B-cell Lymphoma (DLBCL)
Juno Therapeutics, a Subsidiary of Celgene 24
Early research (Phase 1)Active Not RecruitingNCT04288726
What this trial is testing

Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas

Who this might be right for
Extranodal Natural Killer/T-Cell Lymphoma, Nasal TypeClassical Hodgkin Lymphoma
Baylor College of Medicine 27
Early research (Phase 1)Not Yet RecruitingNCT07166549
What this trial is testing

Bispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial)

Who this might be right for
B Cell MalignanciesB-cell LeukemiaB Cell Lymphoma+2 more
University Hospital, Basel, Switzerland 12
Very early researchActive Not RecruitingNCT04134325
What this trial is testing

Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma

Who this might be right for
Relapsed Hodgkin LymphomaRefractory Hodgkin Lymphoma
UNC Lineberger Comprehensive Cancer Center 10
Testing effectiveness (Phase 2)Active Not RecruitingNCT03155191
What this trial is testing

Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia

Who this might be right for
Lymphoblastic Leukemia, Acute Adult
Takara Bio Inc. 21
Early research (Phase 1)UnknownNCT02876978
What this trial is testing

Anti-GPC3 CAR T for Recurrent or Refractory Lung Squamous Cell Carcinoma

Who this might be right for
Lung Squamous Cell Carcinoma
CARsgen Therapeutics Co., Ltd. 20
Testing effectiveness (Phase 2)Looking for participantsNCT04276870
What this trial is testing

Orphan Indications for CD19 Redirected Autologous T Cells

Who this might be right for
Pediatric and Young Adult Patientswith Hypodiploid or t(17;19) B-ALLInfants With Very High Risk KMT2A B-ALLPatients With Central Nervous System Relapse Who Did Not Receive Cranial Radiation or Bone Marrow Transplantation
Stephan Grupp MD PhD 133
Very early researchNot Yet RecruitingNCT07244666
What this trial is testing

Safety and Preliminary Efficacy of a Metabolically Armed Chimeric Antigen Receptor T Cell Therapy Targeting EGFRvIII for Recurrent Glioblastoma

Who this might be right for
Glioblastoma (GBM)
Second Affiliated Hospital, Zhejiang University, School of Medicine 36
Early research (Phase 1)UnknownNCT05381181
What this trial is testing

Safety and Efficacy Evaluation of Next-generation CD19-UCART

Who this might be right for
Acute Lymphoblastic LeukemiaNon Hodgkin Lymphoma
Bioray Laboratories 20
Early research (Phase 1)Looking for participantsNCT05990465
What this trial is testing

LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies

Who this might be right for
Non Hodgkin LymphomaDiffuse Large B Cell LymphomaFollicular Lymphoma+3 more
Medical College of Wisconsin 12
Not applicableWithdrawnNCT05362331
What this trial is testing

Companion for CAR-T Web App During Chimeric Antigen Receptor T-cell Therapy

Who this might be right for
LymphomaLeukemiaPlasma Cell Dyscrasia
University of California, San Francisco
Testing effectiveness (Phase 2)Active Not RecruitingNCT03573700
What this trial is testing

Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia

Who this might be right for
Acute Lymphoblastic Leukemia, in RelapseAcute Lymphoblastic Leukemia, Refractory
St. Jude Children's Research Hospital 24
Next Page